BACKGROUND: There are conflicting reports on the role of fibrates in CVD-risk. Several studies indicate beneficial effects of fibrates on CVD risk in type-2 diabetic patients. We tested how fenofibrate changes lipoprotein subfractions and glucose homeostasis in type-2 diabetic patients. STUDY DESIGN: Selected markers of lipid and glucose homeostasis and inflammation were measured in 204 diabetic patients who participated in the Diabetes Atherosclerosis Intervention Study (DAIS) and were randomly assigned to 200 mg fenofibrate or placebo. Percent changes from baseline until a minimum of 3 years (average 39.6 months) on therapy (end of study) were calculated for all study parameters. RESULTS: The concentrations of total LDL-C and small dense LDL-C (sdLDL-C) did not change on fenofibrate compared to placebo. Compared to placebo, fenofibrate significantly decreased concentrations of triglyceride and remnant-like particle cholesterol (RLP-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA2), while significantly increased concentrations of HDL-C. In contrast to other lipid-modifying drugs (e.g. statins) which increase HDL-C by increasing large (α-1) HDL particles, fenofibrate increased HDL-C by increasing the smaller, less antiatherogenic HDL-C particles, α-3 and α-4. Furthermore, despite lowering TG levels by 20%, fenofibrate failed to decrease pre-β1 levels. On fenofibrate, glycated serum-protein levels increased moderately, while insulin and adiponectin levels did not change. CONCLUSION: On fenofibrate, lipid homeostasis improved and Lp-PLA2 activity decreased while there was no improvement in glucose homeostasis. Despite increasing HDL-C and decreasing triglyceride levels, fenofibrate failed to improve the antiatherogenic properties of the HDL subpopulation profile.
RCT Entities:
BACKGROUND: There are conflicting reports on the role of fibrates in CVD-risk. Several studies indicate beneficial effects of fibrates on CVD risk in type-2 diabeticpatients. We tested how fenofibrate changes lipoprotein subfractions and glucose homeostasis in type-2 diabeticpatients. STUDY DESIGN: Selected markers of lipid and glucose homeostasis and inflammation were measured in 204 diabeticpatients who participated in the Diabetes Atherosclerosis Intervention Study (DAIS) and were randomly assigned to 200 mg fenofibrate or placebo. Percent changes from baseline until a minimum of 3 years (average 39.6 months) on therapy (end of study) were calculated for all study parameters. RESULTS: The concentrations of total LDL-C and small dense LDL-C (sdLDL-C) did not change on fenofibrate compared to placebo. Compared to placebo, fenofibrate significantly decreased concentrations of triglyceride and remnant-like particle cholesterol (RLP-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA2), while significantly increased concentrations of HDL-C. In contrast to other lipid-modifying drugs (e.g. statins) which increase HDL-C by increasing large (α-1) HDL particles, fenofibrate increased HDL-C by increasing the smaller, less antiatherogenic HDL-C particles, α-3 and α-4. Furthermore, despite lowering TG levels by 20%, fenofibrate failed to decrease pre-β1 levels. On fenofibrate, glycated serum-protein levels increased moderately, while insulin and adiponectin levels did not change. CONCLUSION: On fenofibrate, lipid homeostasis improved and Lp-PLA2 activity decreased while there was no improvement in glucose homeostasis. Despite increasing HDL-C and decreasing triglyceride levels, fenofibrate failed to improve the antiatherogenic properties of the HDL subpopulation profile.
Authors: S J Robins; D Collins; J T Wittes; V Papademetriou; P C Deedwania; E J Schaefer; J R McNamara; M L Kashyap; J M Hershman; L F Wexler; H B Rubins Journal: JAMA Date: 2001-03-28 Impact factor: 56.272
Authors: B F Asztalos; P S Roheim; R L Milani; M Lefevre; J R McNamara; K V Horvath; E J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: Bela F Asztalos; Florence Le Maulf; Gerald E Dallal; Evan Stein; Peter H Jones; Katalin V Horvath; Fergus McTaggart; Ernst J Schaefer Journal: Am J Cardiol Date: 2007-01-04 Impact factor: 2.778
Authors: Ron C Hoogeveen; John W Gaubatz; Wensheng Sun; Rhiannon C Dodge; Jacy R Crosby; Jennifer Jiang; David Couper; Salim S Virani; Sekar Kathiresan; Eric Boerwinkle; Christie M Ballantyne Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-20 Impact factor: 8.311
Authors: Bela F Asztalos; Katalin V Horvath; Judith R McNamara; Paul S Roheim; Joel J Rubinstein; Ernst J Schaefer Journal: Atherosclerosis Date: 2002-10 Impact factor: 5.162
Authors: Michael Y Tsai; Brian T Steffen; Weihua Guan; Robyn L McClelland; Russell Warnick; Joseph McConnell; Daniel M Hoefner; Alan T Remaley Journal: Arterioscler Thromb Vasc Biol Date: 2013-11-14 Impact factor: 8.311
Authors: Bela F Asztalos; Dorothea Collins; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer Journal: Metabolism Date: 2008-01 Impact factor: 8.694
Authors: Seul Gee Lee; Seung Jun Lee; Jung Jae Lee; Jung Sun Kim; Oh Hyun Lee; Choong Ki Kim; Darae Kim; Yong Ho Lee; Jaewon Oh; Seil Park; Ok Hee Jeon; Sung Jin Hong; Chul Min Ahn; Byeong Keuk Kim; Young Guk Ko; Donghoon Choi; Myeong Ki Hong; Yangsoo Jang Journal: Korean Circ J Date: 2020-02-12 Impact factor: 3.243